EU OKs two new indications for Novo Nordisk?s Levemir

[Northerner]

There was good news for Danish insulin giant Novo Nordisk (NVO: N) yesterday, when the European Commission approved the extended use of the firm?s basal insulin analogue, Levemir (insulin detemir), in children aged two to five years with type 1 diabetes, making insulin detemir the only basal insulin analogue for use in this young patient group supported by its Summary of Product Characteristics (SmPC).

http://www.thepharmaletter.com/file/108563/eu-oks-two-new-indications-for-novo-nordisks-levemir.html